Compare · CRMD vs NEXT
CRMD vs NEXT
Side-by-side comparison of CorMedix Inc. (CRMD) and NextDecade Corporation (NEXT): market cap, price performance, sector, and recent activity on the wire.
Summary
- CRMD operates in Health Care, while NEXT operates in Utilities - the two are in different parts of the market.
- NEXT is the larger of the two at $1.99B, about 12.8x CRMD ($155.0M).
- CRMD has hit the wire 5 times in the past 4 weeks while NEXT has been quiet.
- NEXT has more recent analyst coverage (16 ratings vs 7 for CRMD).
- Company
- CorMedix Inc.
- NextDecade Corporation
- Price
- -
- -
- Market cap
- $155.0M
- $1.99B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Oil & Gas Production
- Exchange
- AMEX
- NASDAQ
- IPO
- 2015
- News (4w)
- 5
- 0
- Recent ratings
- 7
- 16
CorMedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate DefenCath/Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
NextDecade Corporation
NextDecade Corporation, a liquefied natural gas (LNG) development company, engages in the development activities related to the liquefaction and sale of LNG. It focusses on the development activities of Rio Grande LNG terminal facility located in the Port of Brownsville, southern Texas. The company is headquartered in Houston, Texas.
Latest CRMD
- Today's Stocks in the News
- SEC Form 10-Q filed by CorMedix Inc.
- CorMedix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
- CorMedix Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026
- CorMedix Inc. filed SEC Form 8-K: Other Events
- CorMedix Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant
- SEC Form S-8 POS filed by CorMedix Inc.
- CorMedix Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest NEXT
- SEC Form S-8 filed by NextDecade Corporation
- NextDecade Provides Second Quarter 2026 Business Update
- Goldman initiated coverage on NextDecade with a new price target
- General Counsel De Gyarfas Vera covered exercise/tax liability with 51,935 shares, decreasing direct ownership by 5% to 930,098 units (SEC Form 4) to satisfy tax liability
- Chief Executive Officer Schatzman Matthew K covered exercise/tax liability with 266,531 shares, decreasing direct ownership by 5% to 5,338,853 units (SEC Form 4) (for withholding tax)
- New insider Zuklic John claimed no ownership of stock in the company (SEC Form 3)
- NextDecade Announces Timing of Second Quarter 2026 Investor Call
- NextDecade Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- NextDecade Corporation Announces Pricing of $3.50 Billion Rio Grande LNG, LLC Senior Secured Notes
- NextDecade Corporation Announces Contemplated Notes Sale by Rio Grande LNG, LLC